OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces the change to English as reporting language in order to meet the needs of the Company’s international investors, partners and stakeholders.
In order to effectively meet the needs of the Company’s international investors, partners and stakeholders OncoZenge will be reporting financial, regulatory and other information to the market in English.
The adoption of financial reporting in English will commence as of the publication of the interim report for the period ending the second quarter of 2025, which will be published on August 21, 2025.
BupiZenge™ – Potential to be the leading treatment for oral pain.
For additional information, please contact:
Michael Owens, CFO, mobile: +46 73 324 4988, e-mail: michael.owens@oncozenge.se
Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.
OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.